MJNA Stock Trades at $0.0002 on PNK Exchange, Earnings May 18

Medical Marijuana, Inc. (MJNA) trades at $0.0002 USD on the OTC Pink Markets (PNK) as of May 13, 2026. The company, headquartered in Vista, California, operates in the cannabinoid-based nutraceutical industry with brands like Kannaway and HempMeds. MJNA stock has a market cap of approximately $568,945 with 5.69 billion shares outstanding. The company is scheduled to report earnings on May 18, 2026. Investors tracking MJNA stock should note the company’s recent performance metrics and upcoming financial disclosure. Our AI-powered market analysis platform provides real-time data on this OTC equity.

MJNA Stock Performance and Valuation Metrics

MJNA stock has shown minimal movement recently, with no change on the current trading day. The stock trades well below its 52-week high of $0.0004 and near its 52-week low of $0.0001. Trading volume reached 41.5 million shares, significantly above the average daily volume of 18 million shares. The price-to-sales ratio stands at 0.07, indicating the stock trades at a steep discount to revenue. Track MJNA on Meyka for real-time price updates and technical analysis.

Key Price Levels

The 50-day moving average sits at $0.000189, while the 200-day moving average is at $0.0002085. These technical levels suggest the stock is trading near its intermediate-term average. The day’s trading range was $0.0001 to $0.0002, showing limited intraday volatility. Investors should monitor these moving averages as potential support and resistance zones during upcoming earnings season.

Financial Health and Profitability Analysis

Medical Marijuana, Inc. faces significant profitability challenges reflected in its financial metrics. The company reported a negative EPS of -$0.01 and a negative PE ratio of -0.01, indicating ongoing losses. Net profit margin stands at -7.51%, showing the company loses money on each dollar of revenue generated. Operating margin is -7.27%, reflecting operational inefficiencies. Return on equity is -1.86%, demonstrating poor capital efficiency.

Liquidity and Debt Position

The current ratio of 0.74 indicates potential liquidity concerns, as current liabilities exceed current assets. Working capital is negative at -$1.45 million, suggesting cash flow pressures. Debt-to-equity ratio remains low at 0.05, providing some financial flexibility. The company maintains minimal debt relative to equity, which offers a cushion during challenging periods. However, negative cash flow from operations raises questions about sustainability.

Market Sentiment and Technical Indicators

Technical analysis reveals mixed signals for MJNA stock. The Relative Strength Index (RSI) reads 42.90, suggesting neutral momentum without clear overbought or oversold conditions. The Average Directional Index (ADX) shows 65.53, indicating a strong downtrend is in place. The Commodity Channel Index (CCI) at -116.67 signals oversold conditions, potentially indicating a bounce opportunity. Williams %R at -100 reinforces oversold sentiment.

Trading Activity and Liquidation

On-Balance Volume (OBV) stands at -99.67 million, reflecting sustained selling pressure over time. The Money Flow Index (MFI) at 20.15 confirms weak buying interest and potential liquidation. Rate of Change (ROC) shows -66.67%, indicating significant downward price momentum. These indicators collectively suggest cautious sentiment among traders. The combination of oversold conditions and strong downtrend creates a complex technical picture requiring careful monitoring.

Upcoming Earnings and Investment Considerations

Medical Marijuana, Inc. will announce earnings on May 18, 2026, providing critical insight into operational performance. Meyka AI rates MJNA with a grade of C+, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects the company’s weak profitability but acknowledges its low valuation metrics. These grades are not guaranteed and we are not financial advisors.

Sector Context and Growth Outlook

The company operates in the Drug Manufacturers – Specialty & Generic sector within Healthcare. Revenue growth declined 11.33% year-over-year, indicating market headwinds. However, operating income improved 99.97%, suggesting cost management efforts. The company employs 91 full-time staff and maintains operations across multiple cannabinoid product lines. Recent financial data shows mixed signals, with some operational improvements offset by revenue contraction.

Final Thoughts

MJNA stock is a high-risk investment trading at $0.0002 on OTC Pink Markets. The company faces negative profitability, declining revenue, and cash flow concerns, earning a C+ grade with a HOLD recommendation. While oversold technical conditions and low valuation present potential opportunities, weak fundamentals and liquidity issues require caution. Investors should wait for the May 18 earnings announcement and monitor technical support levels before deciding. This scenario suits experienced traders only.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.